The ANZCTR website will be unavailable from 1pm until 3pm (AEDT) on Wednesday the 30th of October for website maintenance. Please be sure to log out of the system in order to avoid any loss of data.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
ACTRN12616001619437
Ethics application status
Approved
Date submitted
1/11/2016
Date registered
23/11/2016
Date last updated
21/01/2020
Date data sharing statement initially provided
8/01/2019
Type of registration
Prospectively registered

Titles & IDs
Public title
d-mannose for prophylaxis against Urinary tract Infection in Spinal Cord Injury
Scientific title
d-mannose for prophylaxis against Urinary tract Infection in SCI: Pilot Randomised control study
Secondary ID [1] 290435 0
none
Universal Trial Number (UTN)
U1111-1185-0605
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Spinal cord injury 300783 0
Neurogenic Bladder Dysfunction 300920 0
Condition category
Condition code
Renal and Urogenital 300613 300613 0 0
Other renal and urogenital disorders
Neurological 300732 300732 0 0
Other neurological disorders
Infection 300847 300847 0 0
Other infectious diseases

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Mode of administration of d mannose: Oral tablet, 1gm three times a day for 3 months.
Strategies to monitor adherence: Weekly check of medication chart and patient interview.
Intervention code [1] 296281 0
Treatment: Other
Comparator / control treatment
Control: Standard care for neurogenic bladder practised in the spinal unit. This includes, catheter care, early commencement of Intermittent catheterization program in appropriate case, hygiene, good fluid intake with the aim of 1.5 to 2 litres and education.
Control group
Active

Outcomes
Primary outcome [1] 300027 0
Rate ratio of UTI: Number of UTI/Total catheter days.
Number of UTI: This will be assessed by clinical symptoms like temperature more than 38, pain, urinary leakage with positive urine culture.
Catheter days: Total number of days patients needing to use catheter to manage their bladder.
Timepoint [1] 300027 0
3 months post commencement of study treatment.
Secondary outcome [1] 328836 0
Frequency ratio of CUTI: Number of episodes of CUTI between treatment and control group

Number of episode of UTI: Number of symptomatic Urinary tract infection (UTI), this will be assessed by clinical symptoms like fever (temperature more than 38), pain and urinary leakage with positive urine culture.
Timepoint [1] 328836 0
3 months post commencement of study treatment.
Secondary outcome [2] 329182 0
Acute transfer to tertiary Hospital for UTI between two groups.
Medical records and Hospital admission records will be reviewed.
Timepoint [2] 329182 0
3 months post commencement of study treatment.
Secondary outcome [3] 329553 0
Time to first UTI between both groups.
Medcial records review.
Timepoint [3] 329553 0
3 months post commencement of the study.
Secondary outcome [4] 378988 0
Temperature associated CUTI (UTI symptoms and associated temperature elevation) between groups
Temperature associated UTI: defined as temperature more than 38 which is measured using ear thermometer with positive urine culture.
Timepoint [4] 378988 0
3 months

Eligibility
Key inclusion criteria
Study population: patients admitted to Auckland Spinal Rehab Unit (ASRU).
Inclusion criteria: all new admission to spinal unit, neurogenic bladder needing catheter on admission.
Minimum age
14 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
Exclusion criteria: Repeat admission, no evidence of neurogenic bladder on admission.

Study design
Purpose of the study
Prevention
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Allocation is not concealed.
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Simple randomisation using a randomisation table created by computer software (i.e. computerised sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Parallel
Other design features
Phase
Not Applicable
Type of endpoint/s
Efficacy
Statistical methods / analysis
All the statistical analysis will be performed by using one or all of the statistical analytical software: R, SPSS and SAS.
Primary analysis: descriptive summary will be provided for each arm including patients ‘characteristics, number of UTI, time to first UTI within 3 months, need for acute transfer to ED, rate of CAUTI and rate of blood stream associated CAUTI.
Secondary analysis will provide descriptive summary for the safety outcomes by two groups.

Recruitment
Recruitment status
Completed
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment outside Australia
Country [1] 8362 0
New Zealand
State/province [1] 8362 0

Funding & Sponsors
Funding source category [1] 294838 0
Hospital
Name [1] 294838 0
Middlemore Hospital
Country [1] 294838 0
New Zealand
Funding source category [2] 294843 0
Hospital
Name [2] 294843 0
Auckland Spinal rehab unit
Country [2] 294843 0
New Zealand
Primary sponsor type
Individual
Name
Dr Suresh Subramanian
Address
Auckland Spinal Rehab unit
30 bairds Road
Otara
Auckland 1640
Country
New Zealand
Secondary sponsor category [1] 293762 0
None
Name [1] 293762 0
Address [1] 293762 0
Country [1] 293762 0

Ethics approval
Ethics application status
Approved
Ethics committee name [1] 296224 0
Health and Disability Ethics Committee
Ethics committee address [1] 296224 0
Ethics committee country [1] 296224 0
New Zealand
Date submitted for ethics approval [1] 296224 0
Approval date [1] 296224 0
20/10/2016
Ethics approval number [1] 296224 0
16/STH/125/AM01

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes
Attachments [1] 1206 1206 0 0

Contacts
Principal investigator
Name 70074 0
Dr Suresh Subramanian
Address 70074 0
Auckland Spinal rehab unit
30 Bairds Road
Otara
1640
Auckland
Country 70074 0
New Zealand
Phone 70074 0
+64 9 2709000
Fax 70074 0
+64 9 2709001
Email 70074 0
Contact person for public queries
Name 70075 0
Suresh Subramanian
Address 70075 0
Auckland Spinal rehab unit
30 Bairds Road
Otara
1640
Auckland
Country 70075 0
New Zealand
Phone 70075 0
+64 9 2709000
Fax 70075 0
+64 9 2709001
Email 70075 0
Contact person for scientific queries
Name 70076 0
Suresh Subramanian
Address 70076 0
Auckland Spinal rehab unit
30 Bairds Road
Otara
1640
Auckland
Country 70076 0
New Zealand
Phone 70076 0
+64 9 2709000
Fax 70076 0
+64 9 2709001
Email 70076 0

Data sharing statement
Will individual participant data (IPD) for this trial be available (including data dictionaries)?
No
No/undecided IPD sharing reason/comment
Raw data sharing not included in initial ethics application, it will be saved but unable to share .


What supporting documents are/will be available?

Doc. No.TypeCitationLinkEmailOther DetailsAttachment
550Informed consent form    371754-(Uploaded-29-11-2018-13-53-20)-Study-related document.docx
571Ethical approval    371754-(Uploaded-14-12-2018-05-44-51)-Study-related document.pdf



Results publications and other study-related documents

Documents added manually
No documents have been uploaded by study researchers.

Documents added automatically
No additional documents have been identified.